Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
RPX2003 (biapenem) is being studied in combination with a beta-lactamase inhibitor to treat
bacterial infections, including those due to multi-drug resistant bacteria.
Phase:
Phase 1
Details
Lead Sponsor:
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)